Medical Developments International (ASX:MVP) ROCE %: 2.62% (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ASX:MVP Medical Developments International Ltd ASX:MVP
58 GF Score
Price A$0.46
GF Value A$0.52
Valuation Modestly Undervalued
! 2 Warning Signs
View Full Analysis

What is Medical Developments International ROCE %?

Medical Developments International ASX:MVP -7.14% 58 ROCE % is 2.62% as of Jun. 2026. GuruFocus rates ASX:MVP with a GF Score™ of 58/100 and a GF Value™ of A$0.52 (Modestly Undervalued). The stock has 2 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Medical Developments International's annualized ROCE % for the quarter that ended in Jun. 2026 was 2.62%.

Medical Developments International  (ASX:MVP) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Medical Developments International ROCE % Related Terms

Medical Developments International ROCE % Historical Data

* Premium members only.

The historical data trend for Medical Developments International's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Medical Developments International ROCE % Chart

Medical Developments International Annual Data
Trend Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25 Jun26
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -18.07 -8.83 -48.52 0.45 0.97

Medical Developments International Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -62.08 1.31 -0.38 -0.67 2.62
ASX:MVP
58GF Score
Medical Developments International Ltd ASX:MVP
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Medical Developments International ROCE % Calculation

Medical Developments International's annualized ROCE % for the fiscal year that ended in Jun. 2026 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Jun. 2026 )  (A: Jun. 2025 )(A: Jun. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Jun. 2026 )  (A: Jun. 2025 )(A: Jun. 2026 )
=0.569/( ( (66.396 - 7.824) + (64.6 - 6.169) )/ 2 )
=0.569/( (58.572+58.431)/ 2 )
=0.569/58.5015
=0.97 %

Medical Developments International's ROCE % of for the quarter that ended in Jun. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Jun. 2026 )  (Q: Dec. 2025 )(Q: Jun. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Jun. 2026 )  (Q: Dec. 2025 )(Q: Jun. 2026 )
=1.528/( ( (63.568 - 5.56) + (64.6 - 6.169) )/ 2 )
=1.528/( ( 58.008 + 58.431 )/ 2 )
=1.528/58.2195
=2.62 %

(1) Note: The EBIT data used here is two times the semi-annual (Jun. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 2.62% mean?
Medical Developments International (ASX:MVP) has a ROCE % of 2.62% as of Jun. 2026.
Is Medical Developments International's ROCE % too high?
Medical Developments International's current ROCE % is 2.62%. The Drug Manufacturers industry median ROCE % is 7.04. Medical Developments International's value of 2.62% is 62.8% below this industry median. Overall, Medical Developments International has a GF Score™ of 58/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Medical Developments International's ROCE % compare to ZTS?
Medical Developments International's ROCE % of 2.62% can be compared against companies in the Drug Manufacturers industry. The industry median ROCE % is 7.04. Medical Developments International's value of 2.62% is 62.8% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Drug Manufacturers company?
The median ROCE % among Drug Manufacturers companies is 7.04, based on 960 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medical Developments International's current ROCE % of 2.62% is 62.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median ROCE % is 7.04 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medical Developments International's current ROCE % is 2.62%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medical Developments International stock overvalued right now?
Based on GuruFocus' analysis, Medical Developments International (ASX:MVP) is currently considered Modestly Undervalued. The stock's GF Value™ is A$0.52, compared to a current price of A$0.46 — trading 12.5% below its estimated fair value. The current ROCE % is 2.62% and 62.8% below the Drug Manufacturers industry median of 7.04. Medical Developments International's overall GF Score™ is 58/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Medical Developments International (ASX:MVP), the current ROCE % is 2.62% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Medical Developments International (ASX:MVP) Overvalued in 2026?

Based on GuruFocus' analysis, Medical Developments International stock appears to be undervalued. The current stock price of A$0.46 is trading 12.5% below its estimated GF Value™ of A$0.52. GuruFocus considers Medical Developments International to be Modestly Undervalued.

Key valuation signals for ASX:MVP:

  • ROCE %: 2.62%
  • GF Value™: A$0.52 vs. price of A$0.46 (12.5% below fair value)
  • GF Score™: 58/100 with 2 warning signs
  • Industry Position: 62.8% below the Drug Manufacturers median

No single metric tells the full story. See the ASX:MVP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Medical Developments International Business Description

Other Exchanges MDDVF:USAM5D:Germany
Address 4 Caribbean Drive, Scoresby, VIC, AUS, 3179
Medical Developments International Ltd is a specialized healthcare company. The Company manufactures and distributes Penthrox, a fast-acting trauma and emergency pain relief product, used in hospital emergency departments, ambulance services, sports medicine, and for analgesia during short surgical procedures. The segments of the company are Pain Management and Respiratory. The company derives maximum revenue from the Pain management segment.
58GF Score

Get the complete analysis for ASX:MVP

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.46
Price
A$0.52
GF Value